Pluri Appoints Alejandro Weinstein as Chairman of the Board to Lead Strategic Shift and Unlock Value, Backed by Additional Investment
AI Sentiment
Highly Positive
8/10
as of 12-12-2025 4:00pm EST
Pluri Inc is a biotechnology company engaged in the research, development, and manufacturing of cell-based products, as well as the commercialization of cell therapeutics and related technologies aimed at delivering solutions across a range of industries, including regenerative medicine, immunotherapy, food tech, CDMO, and AgTech. The company uses its 3D cell expansion technology platform to develop placenta-based cell therapy product candidates (PLX-PAD and PLX-R18) for the treatment of inflammatory, muscle injuries, and hematologic conditions. In addition, it offers CDMO services through PluriCDMO, has launched a novel immunotherapy platform, and is engaged in developing cultivated, cell-cultured coffee and meat.
| Founded: | 2001 | Country: | Israel |
| Employees: | N/A | City: | HAIFA |
| Market Cap: | 34.9M | IPO Year: | N/A |
| Target Price: | $12.00 | AVG Volume (30 days): | 47.2K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.12 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.02 - $7.13 | Next Earning Date: | 11-12-2025 |
| Revenue: | $1,326,000 | Revenue Growth: | 121.74% |
| Revenue Growth (this year): | 97.38% | Revenue Growth (next year): | 293.97% |
Machine learning model trained on 25+ technical indicators
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
PLUR Breaking Stock News: Dive into PLUR Ticker-Specific Updates for Smart Investing
AI Sentiment
Highly Positive
8/10
See how PLUR stacks up against similar companies in the market
Enhance your trading experience with our free tools
The information presented on this page, "PLUR Pluri Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.